Welcome to our dedicated news page for SeaStar Medical Holding Corporation (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding Corporation .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SeaStar Medical Holding Corporation 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SeaStar Medical Holding Corporation 's position in the market.
SeaStar Medical Holding (Nasdaq: ICU) has been awarded a $3.6 million NIH grant for a clinical trial to evaluate the Selective Cytopheretic Device Adult (SCD-ADULT) in patients with severe chronic heart failure (CHF). The grant aims to study SCD-ADULT as a bridging strategy to left ventricular assist device (LVAD) implantation in patients with acute decompensated heart failure (ADHF). The company hopes this study will pave the way for FDA approval.